CAR-T used in treatment of two men with mCRPC at UPenn
On a CureTalks conversation with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). Read the article here.
CAR-T used in treatment of two men with mCRPC at UPenn Read More »